TL;DR — HMB is a leucine metabolite (~5% of dietary leucine is metabolized to HMB) with the strongest RCT evidence of any supplement for preventing muscle loss during bed rest, hospitalization, and sarcopenia — Deutz 2013 (PMID 23809521) 10-day bed rest in older adults showed HMB fully prevented lean mass loss vs 2.05 kg loss on placebo. Standard dose 3 g/day (as calcium-HMB or free-acid HMB). Not for young trained athletes seeking hypertrophy — the RCTs there are underwhelming. The signal is in preventing loss, not building excess.
What HMB does (and why it matters)
Leucine is the branched-chain amino acid that acutely stimulates mTOR-driven muscle protein synthesis. About 5% of dietary leucine is metabolized (via α-ketoisocaproate → HMB) to β-hydroxy β-methylbutyrate, which:
- Inhibits proteasomal muscle protein degradation (ubiquitin-proteasome pathway, calpain)
- Preserves sarcolemmal membrane integrity during catabolic states
- Stimulates mTORA kinase that acts as a cellular growth sensor — when inhibited, cells shift from growth mode into repair, recycling, and autophagy. Full glossary → modestly, similar to leucine but more anti-catabolic than anabolic
The clinical significance is age-specific. Sarcopenia — the age-related loss of muscle mass and function — is one of the most consequential aging processes (grip strength predicts all-cause mortality independent of chronological age). HMB is one of very few interventions with Tier B RCT evidence for preventing sarcopenic muscle loss.
Primary hallmarks targeted: Stem cell exhaustion (satellite cell function) · Loss of proteostasis (protein turnover balance) · Chronic inflammation (anti-catabolic)
Deutz et al. (2013, PMID 23809521) — 24 older adults (≥65 y) placed on 10-day bed rest — HMB 3 g/day fully preserved lean body mass (vs 2.05 kg loss on placebo). Wu et al. (2015, PMID 25553771) meta of 7 RCTs in older adults — HMB preserved lean mass and reduced hospitalization-associated muscle loss. Bear et al. (2019, PMID 31150038) meta in critical illness — reduced ICU-acquired weakness markers. Kim et al. (2016, PMID 27019027) — HMB + vitamin D + protein combination improved functional outcomes in sarcopenic older adults over 12 weeks.
Mechanism
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| Ubiquitin-proteasome inhibition | ↓ MuRF-1, atrogin-1 → less muscle protein degradation | Proteostasis |
| Sarcolemmal membrane stability | Precursor to cholesterol in muscle → membrane integrity | Proteostasis |
| mTOR modulation | Weak agonist; less potent than leucine | Nutrient sensing |
| Anti-inflammatory | ↓ TNF-α, IL-6 in muscle biopsy | Chronic inflammation |
| Satellite cell function | Preclinical evidence of ↑ satellite cell activation | Stem cell |
The anti-catabolic vs anabolic distinction is why HMB works better in older adults + catabolic states than in trained young athletes. Older muscle is in a chronic net-catabolic state; blocking degradation matters. Young trained muscle is already in net-anabolic state from training; blocking degradation adds little.
When HMB is worth using
HMB earns a place when one or more apply:
- Age 65+ with declining muscle mass, strength, or function
- Planned bed rest, hospitalization, or surgery in older adults (target the Deutz protocol)
- Sarcopenic obesity (loss of muscle with preserved/gained fat)
- Recovery from illness with unintended weight loss
- Adjunct to resistance training in older adults
Skip or defer if you're a healthy young trained athlete (evidence there is weak), have kidney disease requiring protein restriction (discuss with nephrology), or expect HMB alone to substitute for resistance training + protein adequacy (it won't — it's an amplifier, not a replacement).
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Deutz 2013 (PMID 23809521) | RCT (older adults, bed rest) | 24 | 10 d | HMB fully preserved lean mass vs 2 kg loss | B |
| Wu 2015 meta (PMID 25553771) | Meta of 7 RCTs | 287 | Various | ↑ Lean mass, ↑ functional outcomes | B |
| Bear 2019 meta (PMID 31150038) | Meta (ICU) | 15 RCTs | Various | ↓ ICU-acquired weakness markers | B |
| Kim 2016 (PMID 27019027) | RCT (sarcopenia) | 155 | 12 wk | ↑ Strength, function with HMB + D + protein | B |
| Rathmacher 2020 | RCT (older adults + exercise) | 117 | 12 wk | Modest ↑ muscle quality with HMB + training | B |
| Wilson 2013 (young athletes) | Meta | Various | Various | Weak / no consistent hypertrophy effect | C |
← Swipe for more columns →
Consensus: Tier B for preventing muscle loss in older adults, hospitalized patients, and catabolic states. Tier C for muscle-building in healthy young athletes. The age-related sarcopenia use case is what makes this longevity-relevant.
Where HMB disappoints
- Not for young trained athletes. Meta-analyses in that population are underwhelming; the anti-catabolic mechanism doesn't add much when training is already net-anabolic. - Not a shortcut around resistance training. HMB amplifies training effects and prevents loss during rest; it cannot substitute for progressive overload. - Not a substitute for adequate protein intake (1.2–1.6 g/kg/day for older adults). HMB is an add-on; protein is the foundation. - Free-acid HMB vs calcium HMB — free-acid form has faster peak plasma but no clinical outcome differences reported.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Sarcopenia / anti-catabolic | 3 g/day divided TID (1 g × 3) | Standard trial dose |
| Pre-surgery / bed rest prep | 3 g/day starting 5 days before | Deutz protocol |
| Form | Calcium-HMB (most studied) or free-acid HMB (faster peak) | No clinical outcome difference |
| Timing | Split with meals across the day | Steady exposure > single bolus |
| Duration | 4–12 weeks minimum; continuous OK in high-risk older adults | Effects build over weeks |
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Grip strength | Preserved or increasing | Monthly | Add resistance training if flat |
| Lean body mass (DEXA if available) | Preserved or increasing | 3–6 months | Address protein intake first |
| Physical function (SPPB, 6MWT) | Improving | 3 months | Progressive overload training |
| Weight (unintended loss watch) | Stable | Weekly | Escalate care if losing > 1 kg/mo unintentionally |
← Swipe for more columns →
Safety, red flags, and contraindications
- Excellent tolerability at 3 g/day.
- Elevated dietary leucine intake alone provides HMB — supplemental HMB is efficient but not magic.
Do not self-start without clearance
- Advanced chronic kidney disease with protein restriction — additional amino acid load may not be advisable; nephrology-directed.
- Maple syrup urine disease (BCAA metabolism disorder) — contraindicated.
- Pregnancy — insufficient safety data at supplement doses.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Adequate protein (1.2–1.6 g/kg) | HMB is the amplifier; protein is the foundation | Sarcopenia stack |
| Vitamin D3 | Kim 2016 combination showed synergistic functional gain | Sarcopenia stack |
| Creatine monohydrate | Complementary — creatine for PCr buffering, HMB for anti-catabolic | Muscle stack |
| Resistance training | HMB's biggest lever is amplifying training effects | Non-negotiable |
| Acetyl-L-carnitine | Complementary mitochondrial support in aging muscle | Sarcopenia stack |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Prolonged bed rest without HMB | Loss occurs; HMB prevents it | Start HMB before the bed rest, not after |
| Protein-restricted diet | HMB alone can't compensate for inadequate protein | Address protein first |
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.